Costa Rica Regulatory Timeline 2022-2026

1. Key takeaways

Costa Rica’s current device regulation is RTCR 505:2022, approved by Decreto Ejecutivo N° 43902-S on 30 November 2022; Article 7 of the approving decree provides for entry into force 6 months after publication, and Article 4 repeals Articles 1 to 18, 20, 22 and 24 to 30 of DE 34482-S (2008-03-03, La Gaceta N° 80 Alcance 19, 2008-04-25) together with the equivalence procedure DAJ-RM-1151-08. The 2024 amending decree (internal number MS-AJ-CB-200-2024) rewrote Articles 4.7, 10.20, 17.3 and 18.11.4, and extended the label completion window of Transitorio III from 6 months to 18 months. The GRZAN regulatory team notes: the only item in this timeline still counting down is the national BPM regulation — Transitorio IV requires the Ministry of Health to issue it within 12 months of entry into force.

• The main regulation uses a 6-months-after-publication buffer, not force-upon-publication.
• Four transitional provisions handle BPM certificates, existing registered uses, label completion and the BPM rulemaking deadline.
• The 2024 amendment solved CLV sourcing and equivalence-chain breaks, and tripled the label window.
• Repeal and reference replacement operated together: old references to DE 34482-S are read as references to the new decree.
• The formal text states no Gazette number or date, so no calendar effective date is given here.

2. Legal basis

The timeline rests on the approving decree and its transitional provisions, the 2024 amendment, and the earlier decrees that the current regulation references or replaces.

3. Expert insights

Insight one: The main regulation uses a buffer of 6 months after publication. Article 7, Rige 6 meses después de su publicación, gave the industry a half-year adaptation period, during which the four transitional provisions handled BPM (Transitorio I), existing registered uses (Transitorio II), label completion (Transitorio III) and BPM rulemaking (Transitorio IV). This distinguishes the transition from an enter-into-force-on-publication approach. The formal text states no Gazette number or publication date, so this volume gives no calendar effective date.

Insight two: The legislative reasoning of the 2024 amendment is stated very directly. CONSIDERANDO 5° explains the motive for two changes: first, allowing the CLV to be issued by the authority of the country where the holder’s subsidiary is established or where the parent company’s subsidiary is established (the subsidiary must be legally established); second, clarifying that a registration relying on equivalence recognition can no longer rely on it once a CLV issued by a non-recognised authority is submitted, and the full documentation of Articles 11, 12 and 13 must then be submitted. CONSIDERANDO 6° explains that the label window was extended to keep label review from slowing post-registration changes.

Insight three: The extension of Transitorio III is a genuine load reduction. Under the original 6-month window, every dossier without a product label required a dedicated post-registration change; at 18 months, companies can fold label completion into routine changes and save one standalone application. The clock runs from entry into force of the regulation, not from publication of the amendment.

Insight four: Transitorio II resolved the legacy issue of old certificates. Registered uses (usos de registro) approved before entry into force remain valid until the original registration expires, so companies need not concentrate use re-examinations in the transition window; the real pressure point comes at renewal, when the Clase 3 and Clase 4 clinical evidence requirements of the new rules (Article 12.2) apply.

Insight five: BPM is the only unresolved item still counting down. Transitorio I defers the BPM certificate requirements of Articles 11.5, 16.5, 18.9.2, 18.11.1 and 18.16.3, and Transitorio IV requires the Ministry of Health to issue the BPM regulation within 12 months of entry into force. As of the verification date, whether it has been issued remains pending verification against the Ministry of Health’s current publications. The GRZAN regulatory team notes: deferral is not exemption. Once published, the requirement revives simultaneously at five entry points — initial registration (11.5), renewal (16.5) and manufacturer changes (18.9.2, 18.11.1, 18.16.3).

Insight six: Repeal and reference replacement were paired actions. Article 4 of the approving decree repeals the old regulation and the old equivalence procedure, and Article 6 replaces references to DE 34482-S in other decrees with references to the new decree. Old approvals and old equivalence documents should therefore be read under RTCR 505:2022 — their effect was not voided, but redirected.

4. Practical recommendations

• Reconcile historical approvals: for certificates issued under the pre-2022 regulation, confirm under Transitorio II that the registered uses remain valid until the original expiry, and schedule renewal under the new rules after expiry.
• Plan label completion within the 18-month window: where the dossier lacks labels, fold completion into the routine change plan; do not read the 18 months as permission to wait.
• Prepare for BPM on two tracks: obtain and file the target factory’s quality system certificate during the deferral so it can be used directly once published, avoiding submissions at five entry points.
• Rearrange the CLV plan after the 2024 amendment: for groups with capacity in several countries, choose the issuing country under the new 4.7 and confirm the subsidiary is legally established there; where the CLV omits the holder’s name, prepare the declaration letter under the new 10.20.
• Screen for equivalence-chain break risk: for equivalence-based registrations, check case by case whether the current CLV issuing country remains within recognition; where a supplier or site change would change the country of origin, prepare to first-registration standards under the new 18.11.4.
• Maintain annual tracking covering at least the BPM regulation, the recognition list, the official fee schedule and the Regístrelo portal form versions, all per current Ministry publications.

5. Verification checklist

• □ Historical approvals reconciled for use validity and expiry dates
• □ Renewal under the new rules (11 items of Article 16) scheduled for expiring certificates
• □ Dossiers missing labels covered by the 18-month completion window plan
• □ CLV issuing country and subsidiary legal establishment confirmed under the new 4.7
• □ Where the CLV omits the holder, the parent company declaration letter of the new 10.20 is prepared and legalised
• □ Equivalence chain-break risk screened case by case (new 17.3)
• □ Planned site changes altering the country of origin prepared under the new 18.11.4
• □ An alert for publication of the BPM regulation is in place, with quality system evidence interfaced
• □ An annual tracking list exists (BPM regulation, recognition list, fee schedule, portal form versions)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Costa Rican market. Our team manages Ministry of Health (Ministerio de Salud) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com